Caxton Associates (New York)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-4,941
Closed -$738K 492
2019
Q4
$738K Buy
4,941
+1,667
+51% +$227K 0.1% 119
2019
Q3
$420K Buy
+3,274
New +$439K 0.08% 169
2019
Q1
Sell
-1,823
Closed -$226K 440
2018
Q4
$226K Buy
+1,823
New +$270K 0.04% 231

Other funds holding JAZZ

Caxton Associates (New York)'s JAZZ Position: Q1 2020 in Review

Caxton Associates (New York) sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 4,941 shares — an estimated $738K sold.

Caxton Associates (New York) first reported a position in JAZZ in Q4 2018 and held it in 3 quarters. The position peaked at $738K in Q4 2019. 408 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

  • Caxton Associates (New York) reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 4,941 Jazz Pharmaceuticals shares in Q1 2020, an estimated $738K.
  • Caxton Associates (New York) first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Caxton Associates (New York)'s Jazz Pharmaceuticals position peaked at $738K in Q4 2019.
  • 408 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Caxton Associates (New York)'s 13F filing for Q1 2020, filed 15 May 2020.